The Regenerative Medicine Market is expected to reach USD 125.54 billion during the forecast period at a 16.2% CAGR.
From being able to identify and heal life threatening diseases, to their prevention, the health and medicine sector has witnessed a revolutionary development over the years, with regenerative medicine being a major innovation.
Several government organizations and private institutions are investing in the regenerative medicine industry, for research and development. New development is undertaken as per the rules and regulations standardized by organizations like Food and Drug Administration (FDA) in the USA, the European Medicines Agency (EMA) in Europe and other regional authorities.
The average life expectancy of a human being has increased, thus giving rise to the geriatric population. That, coupled with the increasing number of neurodegenerative, orthopedic, oncological, genetic and chronic disorders, constitutes the major factors that are fuelling the growth of the regenerative medicine market size. It has provided a tremendous opportunity to manufacturers, to satisfy this demand of the market. They are collaborating with leading research specialists, labs, pharmaceutical and biotechnology companies, and investors, towards the invention of more regenerative medicines, like gene therapy, nanotechnology, and tissue engineering. The regenerative medicine industry is evolving as one of the most cost-effective and definitive healthcare solutions. Regenerative medicine product analysis shows cell therapy fetching the highest revenue in the forecast period followed by tissue engineering, gene therapy and small molecules and biologics.
North America is expected to hold the highest regenerative medicine market share which invests in oncology and stem cell research. Presence of organizations such as National Cancer Institute, Alliance for Regenerative Medicine, National Institutes of Health and International Society for stem cell research supports the research and development of regenerative medicine which is accelerating the growth in this region. The Asia Pacific region is expected to witness the fastest growth during the forecast period, owing to the population growth in this region. Countries like China and Japan are introducing flexible regulations towards the clinical adoption of regenerative medicine techniques. The government is also actively participating in funding towards the infrastructure required for the research and development. Thus, boosting the global regenerative medicine market further.
Key company profile in the Global Regenerative Medicine Market report are AbbVie, Inc., Baxter International Inc., Becton, Dickinson and Company, Dendreon Pharmaceuticals LLC, F. Hoffmann-La Roche Ltd., FUJIFILM Holdings Corporation, Gilead Sciences, Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson, Medtronic plc, Mesoblast Ltd., Novartis International A.G., NuVasive, Inc., Organogenesis Holdings, Inc., Smith & Nephew plc, Stryker Corporation, Vericel Corporation, and Zimmer Biomet Holdings, Inc.
Regenerative Medicine Market Scope
|Forecast Unit||Value (USD)|
|Segment Covered||Product, Application, Regions|
|Regions Covered||North America, Europe, Asia Pacific, South America, Middle East and South Africa|
Key segments of the Regenerative Medicine Market.
By Material, 2022 to 2030 (USD Billion)
- Synthetic material
- Artificial vascular graft material
- Hydrogel material
- Biologically derived material
By Product, 2022 to 2030 (USD Billion)
- Cell Therapies
- Allogenic Therapies
- Gene Therapies
- Stem Cell Therapies
By Application, 2022 to 2030 (USD Billion)
- Wound Care
- Other Applications
Region Overview, 2022 to 2030 (USD Billion)
- North America
- United States of America
- the Netherlands
- The United Kingdom
- Rest of Europe
- South Korea
- Rest of Asia-Pacific
- South America
- Rest of South America